B. Riley Securities Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $36
Portfolio Pulse from richadhand@benzinga.com
B. Riley Securities analyst Kalpit Patel has maintained a 'Buy' rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raised the price target from $34 to $36.
July 25, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities has maintained a 'Buy' rating on Syndax Pharmaceuticals and raised the price target from $34 to $36.
The maintained 'Buy' rating and increased price target by B. Riley Securities indicates a positive outlook for Syndax Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100